<br />
JANUARY 2012<br />
Pathways<br />
THE CLINICAL TRIALS NETWORK NEWSLETTER<br />
Table of<br />
Contents<br />
2 State of the Network<br />
Address<br />
3 Iodine-123-ioflupane<br />
injection<br />
4 FDA Update on PET<br />
Drugs in Research<br />
Keynote Speaker at<br />
Japanese Symposium<br />
5 CTN Webinar Series<br />
2012<br />
DIA Accepts CTN<br />
Abstract<br />
SNM Cites Advancing<br />
CTN as Key Goal<br />
6 Tech Talk: Career<br />
Options<br />
Research Essentials<br />
7 Neuroimaging<br />
Biomarkers for<br />
Dementia<br />
8 Save the Dates<br />
FDA Guidance for Industry in Clinical Trials:<br />
Experts Weigh In SNM and CTN Leadership<br />
PET imaging has long been used in therapeutic<br />
drug development, especially during Phase I<br />
and II trials. In recent years, Phase III trials<br />
also have incorporated PET imaging studies<br />
as part of a trial’s <a title="37640 page 1" href="http://viewer.zmags.com/publication/71f01926?page=1"> JANUARY 2012 Pathways </a>
<a title="37640 page 2" href="http://viewer.zmags.com/publication/71f01926?page=2"> FDA Guidance for Industry in Clinical Trials Cont</a>
<a title="37640 page 3" href="http://viewer.zmags.com/publication/71f01926?page=3"> BIOMARKER SPOTLIGHT IODINE-123-IOFLUPANE INJECTIO</a>
<a title="37640 page 4" href="http://viewer.zmags.com/publication/71f01926?page=4"> In the NEWS FDA Update on PET Drugs in Research E</a>
<a title="37640 page 5" href="http://viewer.zmags.com/publication/71f01926?page=5"> Clinical Trials Network WEBINAR SERIES 2012 The C</a>
<a title="37640 page 6" href="http://viewer.zmags.com/publication/71f01926?page=6"> CONFIDENCE PAYS OFF Ruth Tesar, CEO, Northern Cal</a>
<a title="37640 page 7" href="http://viewer.zmags.com/publication/71f01926?page=7"> Special FEATURE NEUROIMAGING BIOMARKERS FOR DEMEN</a>
<a title="37640 page 8" href="http://viewer.zmags.com/publication/71f01926?page=8"> Special Feature: References Continued from page 7</a>